

FOSUN PHARMA 复星医药

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海復星醫藥（集團）股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

(Stock Code 股份代號：02196)

NOTIFICATION LETTER 通知信函

11 May 2026

Dear Registered Shareholders.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company")

— Notice of publication of circular of the annual general meeting and 2026 second H shareholders class meeting, notice of the annual general meeting, notice of 2026 second H shareholders class meeting and forms of proxy (collectively the "Current Corporate Communication")

The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website (www.fosunpharma.com) and the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications^(Note). If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed.

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's H share registrar and transfer office in Hong Kong, Tricor Investor Services Limited ("H Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to is-ecom@vistra.com. The Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the H Share Registrar at the above-mentioned address by post or by email to is-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the H Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications ("Notice of Publication") and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the H Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

By Order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Note: Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東：

上海復星醫藥（集團）股份有限公司（「本公司」）

— 股東周年大會及2026年第二次H股類別股東會通函、股東周年大會通告、2026年第二次H股類別股東會通告及代表委任表格（統稱「是次公司通訊」）之登載通知

本公司的是次公司通訊之中，英文版本已分別上載於本公司網站(www.fosunpharma.com)及香港聯合交易所有限公司之網站(www.hkexnews.hk)（「網站版本」）。我們建議閣下閱覽本公司是次及日後公司通訊^(附註)的網站版本。如閣下已選擇收取公司通訊的印刷本，隨函附上是次公司通訊。

如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本，及欲索取是次公司通訊及日後公司通訊的印刷本，請填妥及簽署隨附之回條，並以已預付郵費的郵寄標籤寄回本公司之H股股份過戶登記處（「H股股份過戶登記處」）卓佳證券登記有限公司（地址為香港夏慤道16號遠東金融中心17樓）（如在香港投寄毋須貼上郵票），或電郵至is-ecom@vistra.com。本公司會因應閣下之要求立即寄上是次公司通訊的印刷本，費用全免。

登記股東有責任提供有效的電子郵件地址。如閣下尚未提供閣下之電子郵件地址予本公司，或需更新閣下之電子郵件地址，本公司建議閣下填妥及簽署隨附之回條，並按上述地址以郵寄方式交回本公司的H股股份過戶登記處或以電郵方式發送至is-ecom@vistra.com。如果本公司沒有收到閣下的有效電子郵件地址，直至H股股份過戶登記處收到閣下有效的電子郵件地址前，閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知（「登載通知」）及可供採取行動的公司通訊。本公司將只能以印刷本方式向閣下發送登載通知及可供採取行動的公司通訊之印刷本予閣下。

倘閣下對本通知有任何查詢，請於辦公時間星期一至星期五（公眾假期除外）上午9時至下午6時，致電H股股份過戶登記處熱線(852) 2980 1333。

承董事會命
上海復星醫藥（集團）股份有限公司
董事長
陳玉卿

2026年5月11日

附註： 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括但不限於(a)董事會報告，公司年度帳目連同核數師報告以及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；(f)代表委任表格；及(g)可供採取行動的公司通訊。

可供採取行動的公司通訊是指任何涉及及要求股東指示其擬如何行使其有關股東權利的公司通訊。

